UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Terminated
Unique ID issued by UMIN UMIN000006078
Receipt No. R000007192
Scientific Title A phase II study of Erlotinib as 2nd-line treatment for patients with StageIIIB/IV non-small cell lung cancer
Date of disclosure of the study information 2011/07/30
Last modified on 2018/02/19

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A phase II study of Erlotinib as 2nd-line treatment for patients with StageIIIB/IV non-small cell lung cancer
Acronym A phase II study of Erlotinib as 2nd-line treatment for patients with StageIIIB/IV non-small cell lung cancer
Scientific Title A phase II study of Erlotinib as 2nd-line treatment for patients with StageIIIB/IV non-small cell lung cancer
Scientific Title:Acronym A phase II study of Erlotinib as 2nd-line treatment for patients with StageIIIB/IV non-small cell lung cancer
Region
Japan

Condition
Condition non-small cell lung cancer
Classification by specialty
Pneumology
Classification by malignancy Malignancy
Genomic information YES

Objectives
Narrative objectives1 To evaluate efficacy and safety of Erlotinib as 2nd-line treatment after failure of first-line conbination therapy of Carboplatin/ Paclitaxel/ Bavacizumab for patients with StageIIIB/IV non- squamous non-small cell lung cancer
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1 Exploratory
Trial characteristics_2
Developmental phase Phase II

Assessment
Primary outcomes Response rate
Key secondary outcomes Progression free survival, Adverse events, Overall survival, Response rate of each EGFR status

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Patients were given Erlotinib(150mg/day) until PD or appearing unacceptable toxity.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
75 years-old >=
Gender Male and Female
Key inclusion criteria 1)histologically or cytologically confirmed stage IIIB/IV non-squamous non-small-cell lung cancer
2)Patients who have previously treated with conbination therapy of Carboplatin/ Paclitaxel/ Bavacizumab
3)No prior treatment with HER related agents (gefitinib, lapatinib, trastuzumab, cetuximab, etc.).
4)Patient who has at least one or more measurable lesion by RECIST
5)Performance Status(ECOG) 0-2
6)Patients who can be hospitalized for 1-2 weeks after beginning of the treatment or under management to apply to it.
7)Patients aged 20-75 year old
8)Sufficient function of main organ and normal hematopoietic function, normal liver function and normal renal function filled the following criteria
*Leukocyte counts >= 3,000/mm3
*Neutrophil counts >= 1,500/mm3
*Platelets >= 100,000/mm3
*Hemoglobin concentration >= 9.0 g/dL
*AST and ALT, x 2.5 of upper limit of normal (ULN) or less.
*Total bilirubin <=1.5mg/dL.
*Serum creatinin, x 1.5 of ULN or less.
*Electrocardiogram Nomal
*SpO2 >=90% or SaPO2 >=65mmHg
9)Patients who are considered to survive for more than 3 months.
10)interval:
(1) chemotherapy
*More than 4 weeks after the last chemotherapy.
*More than 2 weeks after the maintenance chemotherapy.
(2) Radiation
*More than 12 weeks after the thoracic irradiation or more than 1 weeks after the last irradiation to other organs.
(3) Operation (including pleurodesis)
*More than 2 weeks after the last operation
11)Patients providing written informed consent
Key exclusion criteria 1)Patients with active lung disease such as interstitial pneumonia, pneumoconiosis, active radiation pneumonitis,or drug-induced pneumonitis
2)Patients with active severe infections
3)Impossible cases with oral administration
4)Patients with active opthalmological disease
5)Pregnancy or lactation
6)Patients with active concomitant malignancy
7)Patients with uncontrollable diabetes mellitus
8)Patients with uncontrollable complications
9)Inappropriate patients for this study judged by the physicians
Target sample size 31

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Yoko Shibata
Organization Yamagata University School of Medicine
Division name Department of Cardiology, Pulmonology, and Nephrology
Zip code
Address 2-2-2 Iida-Nishi, Yamagata-shi,Yamagata 990-9585, Japan
TEL
Email

Public contact
Name of contact person
1st name
Middle name
Last name
Organization Yamagata University School of Medicine
Division name Department of Cardiology, Pulmonology, and Nephrology
Zip code
Address 2-2-2 Iida-Nishi, Yamagata-shi,Yamagata 990-9585, Japan
TEL 023-628-5302
Homepage URL
Email

Sponsor
Institute Yamagata University School of Medicine
Institute
Department

Funding Source
Organization None
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2011 Year 07 Month 30 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Terminated
Date of protocol fixation
2011 Year 05 Month 16 Day
Date of IRB
Anticipated trial start date
2011 Year 07 Month 01 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2011 Year 07 Month 29 Day
Last modified on
2018 Year 02 Month 19 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007192

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.